Not many diseases are as threatening to humanity as cancer. And yet, even with the very significant advances in medical science of the last century, the prognosis for most cancer patients remains poor. The available treatments are often not as effective as needed or highly toxic with poor side effect profiles.
At immatics, we are dedicated to fighting this threat. Our team consists of highly motivated and skilled physicians, biochemists and immunologists.
immatics has a good track record of success: the chances are good that we have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severe side effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development.
We are currently working on the development of new substances for a number of specific cancer types. Our most advanced product is currently been developed in a Phase III clinical trial for kidney cancer with patient recruitment having been completed in Nov. 2012. A second product targeting colorectal cancer has just completed a large Phase I/II clinical trial and a third cancer vaccine has recently entered two Phase I clinical trials in brain cancer. We also have active earlier programs in several other tumor types including gastric cancer and non-small-cell lung cancer.